Novocure releases topline efficacy data from TIGER study for glioblastoma

Novocure “released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma in Germany. The TIGER study enrolled 429 patients who used TTFields therapy between August 2017 and November 2019 and is the largest prospective, non-interventional study of the use of TTFields therapy in routine clinical care completed to date. Median overall survival for patients treated with TTFields therapy was 19.6 months. Median progression-free survival was 10.2 months. TTFields therapy use was not associated with an increase in systemic toxicity and was well tolerated. The outcomes observed in the TIGER study are consistent with the survival and safety results from Novocure’s phase 3 EF-14 clinical trial.”